Herantis Pharma Phase 1 study results of Cis-UCA Eye Drops published

Herantis Pharma Phase 1 study results of Cis-UCA Eye Drops published
Herantis Pharma Plc.
Company release 26 January 2015 at 10:00 am

Results  of the Phase 1 clinical  study of Cis-UCA Eye  Drops of Herantis Pharma
have  been published in  the scientific journal  Acta Ophthalmologica. The peer-
reviewed  article concludes  that topical  ocular administration  of cis-UCA Eye
Drops  three  times  a  day  for  14 days  is safe and well tolerated in healthy

"It is always rewarding to have a drug candidate's safety - one of its essential
attributes  -  confirmed  through  publishing  in an international peer-reviewed
journal",  says  Burkhard  Blank,  MD,  Herantis'  Chief Medical Officer. "It is
exceptionally  exciting  that  it  coincides  with  the recent initiation of our
consecutive Phase 2 efficacy study."

"We  really value the  expertise and high  quality of research  conducted at the
University  of  Eastern  Finland",  adds  Henri  Huttunen,  PhD, Herantis' Chief
Scientific  Officer. "The entire Cis-UCA development  program is a great example
of  what can  be achieved  through a  good university-industry collaboration - a
cornerstone of Herantis."

The  published  article  titled  "A  randomized  phase  I clinical study of cis-
urocanic  acid  eye  drops  in  healthy  adult  subjects"  will  appear  in Acta
Ophthalmologica  and  is  now  available  online  ahead  of  printing  under the
identifier: doi: 10.1111/aos.12651.

Further information:

Herantis Pharma plc., Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site: www.herantis.com
Certified Advisor: UB Capital Oy, telephone: +358 9 2538 0225

About Dry Eye Syndrome

Dry  Eye  Syndrome  (Keratoconjunctivitis  sicca)  is  the  most common cause of
irritation  in  the  eye.  Typical  subjective symptoms include dryness, burning
sensation,  pain, redness, and feeling of dirt in the eye. A severe or prolonged
Dry  Eye Syndrome may lead to complications causing damage to the surface of the
eye  and impaired vision. Dry Eye Syndrome  is expected to become more prevalent
with  the  aging  population  and  with  increasing  use of computers and mobile

About Cis-UCA Eye Drops

Cis-UCA Eye Drops is an ophthalmic solution indicated for the treatment of the
signs and symptoms of Dry Eye Syndrome. Cis-urocanic acid (Cis-UCA), the active
product ingredient of Cis-UCA Eye Drops, is an endogenous small molecule
component of human and animal skin. It is constantly present in the human body
and has been identified as a locally acting anti-inflammatory agent, which also
reduces free radicals.

Cis-UCA Eye Drops has previously been investigated in an experimental model of
dry eye in the mouse, to simulate the Phase 2 clinical study. The results
indicate that 1% Cis-UCA Eye Drops is efficacious in reducing corneal
fluorescein staining in the model and performs better than the clinical
comparator, RestasisĀ®.

About drug development

Drug  development projects can usually be divided in two stages: The preclinical
stage,  and the clinical stage involving  human subjects. The clinical stage can
be  further broken in  three formal phases.  Phase 1 clinical studies assess the
safety of a drug candidate in human subjects. In Phase 2, the optimal dosing and
possible  efficacy in the treatment of a particular disease is studied. Phase 3
studies  finally aim to establish a statistical  proof of safety and efficacy of
the  drug candidate  in typically  hundreds or  thousands of patients for market
approval.  Drug  development  can  take  10-15 years  from the first preclinical
studies to market approval.

About Herantis Pharma Plc.

Herantis  Pharma  Plc.  is  a  pharmaceutical  company  specialised  in new drug
research and development. The company focuses on diseases with an unmet clinical
need.  These diseases include for example dry eye syndrome, Parkinson's disease,
and  secondary lymphedema. We believe  our drugs are the  first or best in their
class  and have  the potential  to change  treatment strategies of diseases. The
shares of Herantis Pharma Plc. are listed on the First North Finland marketplace
run by NASDAQ Helsinki stock exchange.